Assenagon Asset Management S.A. lowered its stake in shares of AC Immune SA (NASDAQ:ACIU - Free Report) by 49.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 223,880 shares of the company's stock after selling 215,850 shares during the period. Assenagon Asset Management S.A. owned 0.23% of AC Immune worth $846,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Silverberg Bernstein Capital Management LLC bought a new stake in shares of AC Immune during the 2nd quarter worth approximately $40,000. Lazard Asset Management LLC bought a new stake in AC Immune in the 1st quarter valued at $30,000. BNP Paribas Financial Markets raised its stake in AC Immune by 315.6% in the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company's stock valued at $33,000 after acquiring an additional 8,423 shares during the period. Vanguard Capital Wealth Advisors bought a new stake in AC Immune in the 2nd quarter valued at $56,000. Finally, Cubist Systematic Strategies LLC bought a new stake in AC Immune in the 2nd quarter valued at $218,000. Institutional investors own 51.36% of the company's stock.
AC Immune Stock Performance
ACIU traded up $0.16 during trading hours on Friday, reaching $3.00. The company's stock had a trading volume of 73,043 shares, compared to its average volume of 76,635. The firm has a market cap of $296.82 million, a PE ratio of -4.17 and a beta of 1.28. The company's 50-day moving average is $3.27 and its 200-day moving average is $3.44. AC Immune SA has a 52 week low of $2.25 and a 52 week high of $5.14.
AC Immune (NASDAQ:ACIU - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.67). The business had revenue of $0.76 million during the quarter, compared to analysts' expectations of $91.60 million. Equities analysts anticipate that AC Immune SA will post -0.89 earnings per share for the current fiscal year.
Analyst Ratings Changes
ACIU has been the topic of a number of research analyst reports. StockNews.com cut AC Immune from a "buy" rating to a "hold" rating in a research note on Tuesday, October 1st. HC Wainwright restated a "buy" rating and issued a $16.00 price target on shares of AC Immune in a research note on Wednesday, September 18th.
View Our Latest Analysis on AC Immune
AC Immune Profile
(
Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Recommended Stories
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
